Evidence map›Paper›PMID 41035653›Full record

ArticleFrontiers in immunology2025

Identification of

Daniel Naumovas, Barbara Rojas-Araya, Catalina M Polanco, Victor Andrade, Rita Čekauskienė, Beatričė Valatkaitė-Rakštienė, Inga Laurinaitytė, Artūras Jakubauskas, Mindaugas Stoškus, Laimonas Griškevičius and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniel NaumovasLaboratory of Nuclease Enabled Cell Therapies, Vilnius University Life Science Center EMBL Partnership Institute for Gene Editing Technologies, Vilnius, Lithuania.
Barbara Rojas-ArayaLaboratory of Nuclease Enabled Cell Therapies, Vilnius University Life Science Center EMBL Partnership Institute for Gene Editing Technologies, Vilnius, Lithuania.
Catalina M PolancoLaboratory of Nuclease Enabled Cell Therapies, Vilnius University Life Science Center EMBL Partnership Institute for Gene Editing Technologies, Vilnius, Lithuania.
Victor AndradeDivision of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany.
Rita ČekauskienėDepartment of Molecular Medicine; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Beatričė Valatkaitė-RakštienėDepartment of Molecular Medicine; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Inga LaurinaitytėVilnius Santaros Klinikos Biobank, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Artūras JakubauskasDepartment of Molecular Medicine; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Mindaugas StoškusDepartment of Molecular Medicine; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Laimonas GriškevičiusDepartment of Molecular Medicine; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Ivan NalvarteKarolinska Institutet, Department of Neurobiology, Care Sciences and Society, BioClinicum, Solna, Sweden.
Jose InzunzaKarolinska Institutet Stem Cell Organoid (KISCO) facility, Department of Laboratory Medicine, Huddinge, Sweden.
Daiva BaltriukienėDepartment of Biological Models, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Jonathan AriasLaboratory of Nuclease Enabled Cell Therapies, Vilnius University Life Science Center EMBL Partnership Institute for Gene Editing Technologies, Vilnius, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human-induced pluripotent stem cells with broad immune compatibility are highly desirable for regenerative medicine applications. Human leukocyte antigen (HLA) class I homozygous cell sources are ideal for immune compatibility modeling. Here, we profile

Indexed as

HLA-A AntigensHLA-B AntigensHLA-C AntigensHomozygoteTissue DonorsAllelesCRISPR-Cas SystemsFemaleGene FrequencyGenotypeHumansInduced Pluripotent Stem CellsMaleHLA-A AntigensHLA-B AntigensHLA-C AntigensHLA class Ihypoimmunogenicimmune compatibilitypopulation geneticssuperdonor

Identifiers

PMID41035653
PMCPMC12479312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.